96 Results for "

CD3 T cells

" in MedChemExpress (MCE) Product Catalog:
Products (96)

96 Results for "CD3 T cells" in MCE Product Catalog:

3
Blinatumomab
Blinatumomab
0 Images
3 Cited Publications
Referencia número: HY-P9963
No. CAS: 853426-35-4
Synonyms: bscCD19xCD3; AMG-103; MEDI-538; MT-103; BLINCYTO

Target:  

CD19

Áreas de investigación:  

Cancer

Blinatumomab (Anatumomab) is a bispecific monoclonal antibody with two binding sites, one for CD3E on T cells and one for CD19 on B cells. Blinatumomab can be used in research for acute lymphoblastic leukemia .
loading...
    loading...
View All Sizes
2
Tarlatamab
Tarlatamab
0 Images
2 Cited Publications
Referencia número: HY-P99575
No. CAS: 2307488-83-9
Synonyms: AMG-757

Target:  

Notch

Áreas de investigación:  

Inflammation/Immunology Cancer

Tarlatamab (AMG-757) is a bispecific T-cell engager (BiTE) antibody targeting delta-like ligand 3 (DLL3). DLL3 is a target that is selectively expressed in small-cell lung cancer (SCLC) tumors, but with minimal normal tissue expression. Tarlatamab has the KDs of 0.64 nM and 0.50 nM for human and nonhuman primate (NHP) DLL3, respectively. Tarlatamab has the KDs of 14.9 nM and 12 nM for human and NHP CD3, respectively. Tarlatamab is a first-in-class HLE BiTE immuno-oncology therapy targeting DLL3 and has the potential for SCLC research .
loading...
    loading...
View All Sizes
2
Epcoritamab
Epcoritamab
0 Images
2 Cited Publications
Referencia número: HY-P99931
No. CAS: 2134641-34-0
Synonyms: GEN3013

Target:  

CD3 CD20

Áreas de investigación:  

Cancer

Epcoritamab (GEN3013) is an bispecific IgG1 antibody redirecting T-cells toward CD3×CD20 + tumor cells. Epcoritamab induces potent T-cell-mediated cytotoxicity towards B-cell NHL cell lines .
loading...
    loading...
View All Sizes
2
Amlitelimab
Amlitelimab
0 Images
2 Cited Publications
Referencia número: HY-P99434
No. CAS: 2378692-15-8
Synonyms: KY1005; SAR445229

Target:  

Inhibitory Antibodies

Áreas de investigación:  

Inflammation/Immunology

Amlitelimab () is an anti-OX40 Ligand (OX40L) monoclonal antibody (mAb). Amlitelimab inhibits OX40-OX40L interaction, and can be used in the research of atopic dermatitis .
loading...
    loading...
View All Sizes
2
Cibisatamab
Cibisatamab
0 Images
2 Cited Publications
Referencia número: HY-P99011
No. CAS: 1855925-27-7
Synonyms: RG-7802; RO-6958688; CEA-TCB

Target:  

CD3

Áreas de investigación:  

Cancer

Cibisatamab, a T cell bispecific antibody, binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells. Cibisatamab triggers T cell killing of cancer cell lines expressing moderate to high levels of CEA at the cell surface. Cibisatamab can be used for colorectal cancer research .
loading...
    loading...
View All Sizes
2
Human CD3/CD28 T Cell Activation Magnetic Beads
Human CD3/CD28 T Cell Activation Magnetic Beads
0 Images
2 Cited Publications
Referencia número: HY-K0353

MCE Human CD3/CD28 T Cell Activation Magnetic Beads are based on the two important co-stimulatory signals, without relying on feeder cells (antigen-presenting cells) or antigens, CD3 and CD28, without relying on feeder cells (antigen-presenting cells) or antigens, enabling simple and rapid T cell activation.

loading...
    loading...
View All Sizes
1
Mosunetuzumab
Mosunetuzumab
0 Images
1 Cited Publications
Referencia número: HY-P99033
No. CAS: 1905409-39-3
Synonyms: BTCT-4465A; RG-7828; RO7030816

Target:  

CD20 CD3

Áreas de investigación:  

Inflammation/Immunology Cancer

Mosunetuzumab (BTCT-4465A) is a full-length, fully humanized immunoglobulin G1 (IgG1) T-cell-dependent bispecific (TDB) antibody targeting CD20 (B cells) and CD3 (T cells). Mosunetuzumab redirects T cells to engage and eliminate malignant B cells and can be used for the research of relapsed or refractory (R/R) B-cell non-Hodgkin lymphomas (B-NHLs) .
loading...
    loading...
View All Sizes
1
Glofitamab
Glofitamab
0 Images
1 Cited Publications
Referencia número: HY-P99024
No. CAS: 2229047-91-8
Synonyms: RO7082859; RG-6026

Target:  

CD20 CD3

Áreas de investigación:  

Inflammation/Immunology Cancer

Glofitamab (RO7082859) is a T-cell-engaging bispecific antibody possessing a novel 2:1 structure with bivalency for CD20 on B cells and monovalency for CD3 on T cells. Glofitamab leads to T-cell activation, proliferation, and tumor cell killing upon binding to CD20 on malignant cells. Glofitamab induces durable complete remissions in relapsed or refractory B-Cell non-Hodgkin lymphoma (B-NHL) .
loading...
    loading...
View All Sizes
1
Talquetamab
Talquetamab
0 Images
1 Cited Publications
Referencia número: HY-P99394
No. CAS: 2226212-40-2
Synonyms: JNJ-64407564

Target:  

CD3

Áreas de investigación:  

Cancer

Talquetamab (JNJ-64407564) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab (JNJ-64407564) has antitumor activity .
loading...
    loading...
View All Sizes
1
Pasotuxizumab
Pasotuxizumab
0 Images
1 Cited Publications
Referencia número: HY-P99802
No. CAS: 1442657-12-6
Synonyms: BAY 2010112; AMG 212; MT112

Target:  

CD3

Áreas de investigación:  

Cancer

Pasotuxizumab (BAY 2010112) is a PSMA and CD3 bispecific T-cell engager (BiTE). Pasotuxizumab binds to CD3 and PSMA with KDs of 9.4 nM and 47.0 nM for human CD3 and PSMA. Pasotuxizumab can be used for research of metastatic castration-resistant prostate cancer (mCRPC) .
loading...
    loading...
View All Sizes
1
Obrindatamab
Obrindatamab
0 Images
1 Cited Publications
Referencia número: HY-P99762
No. CAS: 2069959-72-2
Synonyms: MGD009

Target:  

CD3

Áreas de investigación:  

Cancer

Obrindatamab is a humanized anti-B7-H3/CD3 bispecific antibody. Obrindatamab binds to B7-H3 and CD3, thereby mediating redirected cytotoxic T-lymphocyte (CTL) activity against B7-H3-expressing cancer cells. Obrindatamab can be used in research of cancer .
loading...
    loading...
View All Sizes
1
Gresonitamab
Gresonitamab
0 Images
1 Cited Publications
Referencia número: HY-P99350
No. CAS: 2413817-97-5
Synonyms: AMG 910; Anti-Human CD3xClaudin18 2

Target:  

CD3

Áreas de investigación:  

Cancer

Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .
loading...
    loading...
View All Sizes
1
Anti-Mouse CD3 Antibody (17A2)
Anti-Mouse CD3 Antibody (17A2)
0 Images
1 Cited Publications
Referencia número: HY-P99124

Target:  

CD3

Áreas de investigación:  

Inflammation/Immunology

Anti-Mouse CD3 Antibody (17A2) is an anti-mouse CD3 IgG2b antibody inhibitor derived from the host Rat. Anti-Mouse CD3 Antibody (17A2) enhances T-cell proliferation and activation and stimulate IFN-γ or IL-17 production in splenic T cells. Anti-Mouse CD3 Antibody (17A2) significantly suppresses mortality in Graft-versus-host disease (GVHD) mice models .
loading...
    loading...
View All Sizes
1
Pavurutamab
Pavurutamab
0 Images
1 Cited Publications
Referencia número: HY-P99814
No. CAS: 2250292-39-6
Synonyms: AMG-701

Target:  

CD3

Áreas de investigación:  

Inflammation/Immunology Cancer

Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .
loading...
    loading...
View All Sizes
1
Human CD3+ T Cells Negative Selection Kit
Human CD3+ T Cells Negative Selection Kit
0 Images
1 Cited Publications
Referencia número: HY-K0304

MCE Human CD3+ T Cells Negative Selection Kit is designed for the isolation of CD3+ T cells from human peripheral blood mononuclear cells (PBMC).

loading...
    loading...
View All Sizes
1
Mouse CD3+ T Cells Negative Selection Kit
Mouse CD3+ T Cells Negative Selection Kit
0 Images
1 Cited Publications
Referencia número: HY-K0306

MCE Mouse CD3+ T Cells Negative Selection Kit is designed for the isolation of CD3+ T cells from single cell suspensions of mouse spleen cells and lymph nodes.

loading...
    loading...
View All Sizes
Teclistamab
Teclistamab
0 Images
Referencia número: HY-P99392
No. CAS: 2119595-80-9
Synonyms: JNJ-7957; JNJ-64007957; Tecvayli

Target:  

CD3

Áreas de investigación:  

Cancer

Teclistamab is a human bispecific antibody to BCMA and CD3 that recognizes BCMA on target cells and CD3 on T cells and induces T cell-mediated cytotoxicity leading to T cell activation and subsequent target cell lysis. Teclistamab can be used in studies of diseases related to multiple myeloma (MM) .
loading...
    loading...
View All Sizes
Cevostamab
Cevostamab
0 Images
Referencia número: HY-P99601
No. CAS: 2249888-53-5
Synonyms: BFCR 4350A; RG 6160; RO 7187797

Target:  

CD3

Áreas de investigación:  

Neurological Disease Cancer

Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells .
loading...
    loading...
View All Sizes
Surovatamig
Surovatamig
0 Images
Referencia número: HY-P991028
No. CAS: 2892667-02-4
Synonyms: AZD0486; TNB-486

Target:  

CD3 CD19 Interleukin Related TNF Receptor IFNAR

Áreas de investigación:  

Cancer

Surovatamig (AZD0486; TNB-486) is a fully human anti-CD19/CD3 IgG4 bispecific antibody. Surovatamig triggers T cell activation, releases cytotoxic granules, and induces T cell-dependent cellular cytotoxicity and tumor cell lysis. Surovatamig can reduces release of pro-inflammatory cytokines including IL-2, IFNγ, TNF. Surovatamig can be used for the research of cancer, such as B cell non-Hodgkin lymphoma .
loading...
    loading...
View All Sizes
Xaluritamig
Xaluritamig
0 Images
Referencia número: HY-P990688
No. CAS: 2559056-68-5
Synonyms: AMG-509

Target:  

CD3

Áreas de investigación:  

Cancer

Xaluritamig (AMG-509) is a bispecific T cell engager and cytolytic agent with a Kd of 27.6 nM for human CD3ε. Xaluritamig binds to CD3ε via an anti-CD3 single-chain variable fragment (scFv) domain, and to STEAP1 via a bispecific anti-STEAP1 antigen-binding fragment (Fab) domain, thereby recruiting and activating T cells and forming a bridge between T cells and STEAP1-expressing cancer cells. Xaluritamig induces T cell-mediated redirected cytotoxicity, tumor cell lysis, cytokine release, CD8 + T cell activation and expansion, as well as tumor stasis or regression. Xaluritamig contains an Fc domain with no effector function, which prolongs serum half-life, exhibits only minimal activity against cells with low STEAP1 expression and normal cells, and shows extremely low target-related off-tumor toxicity in cynomolgus monkeys. Xaluritamig is used in STEAP1×CD3 XmAb 2+1 immunotherapy and in research on metastatic castration-resistant prostate cancer and Ewing sarcoma .
loading...
    loading...
View All Sizes
Assay Types